Table 2.
Survival analyses of prognostic factors
| No. patients | OS | DSS | ||||||
|---|---|---|---|---|---|---|---|---|
| MST (days) | 95% CI | P value | MST (days) | 95% CI | P value | |||
| Age (years) | < 70 | 58 | NA | NA | 0.164 | NA | NA | 0.272 |
| ≥ 70 | 70 | 2497 | NA | NA | NA | |||
| Sex | male | 97 | NA | NA | 0.315 | NA | NA | 0.487 |
| female | 31 | 2473 | 981–3965 | NA | NA | |||
| BMI | < 25 | 108 | NA | NA | 0.907 | NA | NA | 0.491 |
| ≥ 25 | 20 | NA | NA | NA | NA | |||
| Neoadjuvant chemotherapy | yes | 41 | 849 | 359–1339 | < 0.001a | 875 | 616–1134 | < 0.001 a |
| no | 87 | NA | NA | NA | NA | |||
| Adjuvant chemotherapy | yes | 11 | 1120 | 716–1524 | < 0.001 a | 1285 | 784–1786 | < 0.001 a |
| no | 117 | NA | NA | NA | NA | |||
| Stage (UICC 7th) | I | 62 | NA | NA | 0.001 a | NA | NA | < 0.001 a |
| II/III/IV | 66 | 1430 | 264–2596 | 1811 | NA | |||
| Histlogical type | poor/sig | 64 | NA | NA | 0.199 | NA | NA | 0.467 |
| well/mod/other | 64 | 2291 | NA | NA | NA | |||
| Vascular invasion | negative | 47 | NA | NA | 0.030 a | NA | NA | 0.005 a |
| positive | 81 | 2345 | NA | NA | NA | |||
| Lymphatic invasion | negative | 41 | NA | NA | 0.027 a | NA | NA | 0.005 a |
| positive | 87 | 2473 | NA | NA | NA | |||
| pT | I/II | 72 | NA | NA | 0.011 a | NA | NA | < 0.001 a |
| III/IV | 56 | 1430 | 682–2178 | 1574 | NA | |||
| pN | 0 | 73 | NA | NA | < 0.001 a | NA | NA | < 0.001 a |
| 1 | 55 | 1187 | 711–1663 | 1293 | 512–2074 | |||
| CEA (ng/mL) | < 5 | 113 | NA | NA | 0.664 | NA | NA | 0.641 |
| ≥ 5 | 15 | NA | NA | NA | NA | |||
| CA19-9 (U/mL) | < 35 | 98 | NA | NA | 0.895 | NA | NA | 0.440 |
| ≥ 35 | 30 | NA | NA | NA | NA | |||
| Liver metastasis | presence | 15 | 664 | 394–934 | < 0.001 a | 664 | 394–934 | < 0.001 a |
| absence | 113 | NA | NA | NA | NA | |||
| Peritoneal dissemination | presence | 20 | 699 | 305–1093 | < 0.001 a | 699 | 305–1093 | < 0.001 a |
| absence | 108 | NA | NA | NA | NA | |||
| AMIGO2 | low | 99 | NA | NA | 0.004 a | NA | NA | < 0.001 a |
| high | 29 | 977 | 725–1229 | 1103 | 0–2587 |
OS overall survival, DSS disease-specific survival, CI confidence interval, MST median survival time, BMI body mass index, sig/poor/mod/well signet-ring cell/poorly/moderately/well differentiated, pT/N pathological T/N stage, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen19-9, NA not applicable, astatistically significant